Streetbeat News

EPIX

ESSA Pharma Inc.

https://www.essapharma.com

Industry

Biotechnology

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Oppenheimer analyst Leland Gershell maintains an Outperform rating on ESSA Pharma (NASDAQ:EPIX) with a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 1:41 pm

ESSA Pharma (NASDAQ:EPIX) reported Q1 earnings on February 13, 2024, beating estimated earnings by 17.65% with an EPS of $-0.14 versus an estimate of $-0.17. However, revenue remained unchanged from the same period last year. In the previous quarter, ESSA Pharma's EPS beat led to a 0.36% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 2:10 pm

ESSA Pharma (NASDAQ:EPIX) has delivered an average annual return of 15.65% over the past 5 years, outperforming the market by 3.09% annually. A $1000 investment in EPIX 5 years ago would now be worth $2,060.30. ESSA Pharma's market cap stands at $297.22 million.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:06 pm

ESSA Pharma Inc (NASDAQ:EPIX) shares dropped 22.6% to close at $6.80 after presenting updated data from a Phase 1/2 study of masofaniten in combination with enzalutamide for prostate cancer treatment. The study showed positive results, with significant reductions in PSA levels among patients. Despite the promising data, the stock experienced a significant decline. The company has sufficient cash to fund operations through 2025. EPIX stock is down 1.03% in premarket trading.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 1:51 pm

In Tuesday's pre-market session, several stocks are moving higher despite lower U.S. stock futures, with Nasdaq futures down about 100 points. MorphoSys AG (MOR) shares jumped 18.8%, ESSA Pharma Inc. (EPIX) gained 10.6% after a 17% surge on Friday, Digital World Acquisition Corp. (DWAC) increased by 8.3%, ZIM Integrated Shipping Services Ltd. (ZIM) climbed 5.7%, Nomura Holdings, Inc. (NMR) rose by 5.3%, Tilray Brands, Inc. (TLRY) went up by 4.8%, and Applied Digital Corporation (APLD) gained 3.7% ahead of its quarterly earnings release.

Portfolio Pulse from Avi Kapoor

January 16, 2024 | 10:53 am

Oppenheimer analyst Mark Breidenbach has reiterated an Outperform rating on ESSA Pharma (NASDAQ:EPIX) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 4:36 pm

ESSA Pharma (NASDAQ:EPIX) reported a narrower Q4 loss of $(0.12) per share compared to $(0.14) per share in the same quarter last year. The company also reported a cash balance of $148.1M, which is expected to fund its operations through 2025.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 12:05 pm

ESSA Pharma (NASDAQ:EPIX) reported Q4 earnings with an EPS of $-0.12, beating estimates by 42.86% against an expected $-0.21. However, revenue was down $0 from the same period last year. In the previous quarter, ESSA Pharma's EPS beat led to a 0.36% drop in share price the following day.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 12:05 pm

Essa Pharma has announced its intention to offer and sell common shares with an aggregate offering price of up to $50M. The sales will be conducted from time to time through Jefferies.

Portfolio Pulse from Charles Gross

November 06, 2023 | 11:10 am

ESSA Pharma Inc. (NASDAQ:EPIX) has announced updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide for the treatment of prostate cancer. The data, presented at the ESMO 2023 Congress, shows that the combination is well tolerated and results in significant reductions in prostate-specific antigen (PSA) in patients with metastatic castration-resistant prostate cancer (mCRPC). Across all cohorts, 69% of patients achieved PSA90, 63% achieved PSA90 in less than 90 days, and 56% achieved PSA <0.2mg/mL.

Portfolio Pulse from Charles Gross

October 21, 2023 | 1:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.